Articles tagged with Ovarian Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers identified a molecule called AXL which triggers the spread of an aggressive form of ovarian cancer. Blocking AXL may be an effective treatment option for patients with Mes subtype ovarian cancer.
Researchers at Case Western Reserve University developed a new method called InFlo to assess cell communication networks and identify disease-specific anomalies. InFlo predicts how cells send signals across networks to cause cancer or other disease, with applications in basic and translational research.
Researchers at Georgia Tech develop a targeted therapy using nanoparticles to deliver short interfering RNA that knocks down EGFR protein, leading to massive reduction or complete eradication of ovarian cancer tumors. The treatment, combined with chemotherapy, shows promising results in limited in vivo tests on mice.
Researchers at The Wistar Institute have developed a combination therapy that improves chemoresistance in ovarian cancer. BET inhibitors can suppress ALDH activity, making treatment more effective when used with cisplatin. This approach has shown extended survival rates and delayed tumor growth in mice.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
Research from Kumamoto University has discovered that a natural compound isolated from onions, onionin A, exhibits anti-ovarian cancer properties. ONA inhibits the growth of ovarian cancer cells and enhances the effects of anti-cancer drugs, making it a promising treatment option.
PharmaMar announces completion of Phase 3 pivotal study CORAIL with lurbinectedin (PM1183) for platinum-resistant ovarian cancer. The study demonstrates potential therapeutic alternative for patients who relapse after standard treatment. PharmaMar has successfully recruited 443 patients from over 100 hospitals in Europe and the USA.
New research from The Wistar Institute found that estrogen signaling is responsible for immunosuppressive effects in the tumor microenvironment across various cancers. This discovery paves the way for combining anti-estrogen therapy with immunotherapeutic treatments to extend survival in patients.
The ENGOT-OV16/NOVA trial shows niraparib significantly improves progression-free survival in recurrent ovarian cancer patients, with median survival rates up to 21 months. Niraparib also improves secondary endpoints, including time to first subsequent treatment and chemotherapy-free interval.
Researchers at The Wistar Institute discovered that BET inhibitors can suppress PD-L1 activity, a major therapeutic target in various tumors. This approach may reduce side effects while enhancing the immune response against cancer.
Global trends show a decline in ovarian cancer deaths in the EU and USA between 2002 and 2012, with declines also seen in Australia and New Zealand. The main reason is the use of oral contraceptives, which provide long-term protection against ovarian cancer.
The Independent Data Monitoring Committee approved PharmaMar's CORAIL study of PM1183 in patients with platinum-resistant ovarian cancer. The pivotal Phase III trial evaluates the efficacy of PM1183 compared to standard treatments.
A recent study by the Medical University of South Carolina found that African American women with lower socioeconomic status are at a higher risk of developing ovarian cancer. The study revealed a significant inverse association between SES and ovarian cancer risk, with women having a college degree or higher experiencing a 29% lower r...
Researchers have found a way to detect ovarian cancer early using a protein test, providing new hope for patients. An enzyme called SIK2 has been identified as key in making ovarian cancer more deadly, offering a potential new treatment target.
Researchers have identified BRCA1 mutations that predict treatment resistance in breast and ovarian cancers. Studies found that tumors with these mutations express a RING-deficient BRCA1 protein, leading to poor treatment responses.
Researchers at Mayo Clinic developed a new method to detect ovarian cancer recurrence using liquid biopsies from blood tests and DNA sequencing. This approach allows for earlier intervention and more effective individualized treatment by monitoring genetic changes in circulating cell-free DNA.
A new streamlined approach to genetic testing for women with ovarian cancer allows for faster and more affordable testing, enabling personalized cancer management and cancer prevention strategies. The test has been widely adopted in the UK and internationally, with estimates suggesting it could save £2.6M per year.
A new study shows that removing fallopian tubes during hysterectomies can help prevent ovarian cancer without compromising surgical outcomes. The procedure has been widely adopted in Kaiser Permanente's Northern California system, with no increase in complications or length of stay.
Researchers at Cold Spring Harbor Laboratory have identified a new pathway in ovarian cancer cells that can be targeted by drugs, reducing metastasis. The newly uncovered pathway depends on activity of protein FER, which activates receptor MET, leading to elevated motility and invasiveness.
A new study published in ecancermedicalscience found that online information about ovarian cancer can cause as much worry as comfort for women at high risk. The researchers suggest that patients should seek guidance from healthcare professionals and credible websites to make informed decisions.
A study published in JAMA Oncology found that women with the BRCA1 gene mutation have a significantly higher risk of developing serous endometrial cancer, which has a mortality rate of 50%. The study suggests that women with this genetic mutation should consider removing their uterus along with their ovaries and fallopian tubes. Resear...
A recent study has identified over 200 proteins involved in cell movement and immune system function that are implicated in ovarian cancer progression. By analyzing the proteomes of 169 ovarian cancer patients, researchers have gained new insights into the biology of the disease and potential targets for treatment.
Scientists analyzed 169 ovarian cancer tumors to identify key proteins, revealing new molecular events in high-grade serous carcinoma. This proteogenomics approach combines genomic and proteomic data to improve understanding of the disease, with potential applications for precision medicine and pharmaceutical interventions.
Researchers found a strong five-gene signature in all patients who succumbed to the disease, regardless of their length of survival. The team also tested HXR9, which blocked HOX gene function, forcing cancer cells to close down and die, and found that combining it with cisplatin significantly increased cancer cell killing.
Researchers propose reducing the threshold for pre-emptive surgery on women at high risk of ovarian cancer from 10% to 4%. This could add up to 43 extra days of life expectancy if hormone replacement therapy is taken. The procedure would be cost-effective and help compensate for the lack of a reliable test.
A ketogenic diet has shown promise in reducing tumor size and progression in ovarian cancer, with a new clinical trial aiming to replicate these results in humans. The trial aims to investigate the effects of a low-carbohydrate diet on ovarian cancer patients' quality of life and cancer-related measures.
Research reveals five major ways microRNAs contribute to chemoresistance in epithelial ovarian cancer (EOC). Targeting cell cycle regulation, apoptosis, drug transporters, tumor suppressor roles, and signaling pathways can help reverse resistance. This knowledge highlights the therapeutic potential of miRNAs.
Research suggests that patients with advanced ovarian cancer who underwent pre-surgical chemotherapy showed altered immune cells in their tumors, indicating a potential increase in effectiveness of immunotherapy after treatment. This study found evidence of activation of certain T cells and reduction of immune suppressive cells in pati...
Researchers discovered that chemotherapy activates immune cells T cells within tumours, but also boosts cancer defences against immune attack. Effective immunotherapy treatments will have to block PD-L1 protein to target tumours effectively.
Dr. Glen Weiss presents five innovative cancer studies at ASCO, including liquid biopsies for predicting treatment improvements and promising results with avelumab against recurrent-refractory ovarian cancer. Brigatinib shows substantial antitumor activity in ALK non-small cell lung cancer patients.
A study published at the American Society of Clinical Oncology Annual Meeting found bacteria in women's ovaries and fallopian tubes. Women with ovarian cancer have distinct bacterial profiles, suggesting potential links to cancer development or progression.
Researchers are developing imaging biomarkers and optical imaging tools to screen for ovarian cancer, a 'silent killer' of women. The goal is to enable early detection and save lives.
Researchers found that nearly half of women over 75 with stage III/IV cancer do not have surgery, while black and American Indian women are 35% less likely to receive surgery than white women. Surgical treatment is associated with a fourfold increase in survival for patients.
Research finds radically-altered subcellular activity in women carrying BRCA1/2 mutations, opening door to new preventative strategies and non-invasive test development. These changes were similar to those seen in ovarian cancer specimens, providing hope for reducing invasive surgery.
Researchers at Boston University School of Medicine found similarities in genetic and epigenetic alterations between breast and ovarian cancers. The study suggests that better understanding of these changes may lead to more effective chemotherapeutics and strategies to circumvent drug resistance.
Researchers discovered that immune T cells can overcome chemotherapy resistance in ovarian cancer by outsmarting fibroblasts. By boosting these immune cells, the tumor cells begin to die off, suggesting a new approach to treating ovarian cancer.
A new approach could help women of reproductive age preserve their fertility during cancer treatment by targeting DNA damage response in oocytes. This method has shown promise in animal models and may prevent premature ovarian insufficiency and infertility.
Dr. Nita Maihle is leading a national DOD initiative to support early career ovarian cancer investigators. The program aims to foster team science and improve understanding of the disease. With a focus on secretory cells that line the fallopian tubes, researchers hope to develop targeted therapies for this deadly form of cancer.
A new study published in Cell Reports identifies microRNA molecule miR551b as a promising candidate biomarker and therapeutic target for treating ovarian cancers. The research found that targeting miR551b expression could block STAT3 activity, offering potential for treating the most common and deadly form of ovarian cancer.
A new study by researchers at the University of Pennsylvania's Abramson Cancer Center found that testing non-breast cancer genes in high-risk women does not add clinical benefit. The study analyzed a large panel of genes and found that many variants were of uncertain significance, adding complexity to genetic counseling.
A study of 36 women found nearly all carried cancer-associated gene mutations, suggesting high accuracy and sensitivity for detecting ovarian cancer. Duplex sequencing technology can identify low-frequency cancer-like mutations, potentially leading to early detection and treatment.
A study published in Human Reproduction found that women with BRCA1 gene mutations have lower levels of anti-Müllerian hormone, indicating reduced ovarian reserves. This may impact fertility and suggest a need for earlier pregnancy planning.
A Phase 1/2 clinical trial is being conducted to evaluate the combination of MedImmune's durvalumab and VentiRx's motolimod in locally advanced or recurrent ovarian cancers. The study aims to assess the safety and efficacy of the combination, with a focus on enhancing anti-tumor immune responses.
Researchers have discovered a molecular fingerprint of some deadly cancers, including a genomic configuration called the tandem duplicator phenotype (TDP) that is enriched in triple-negative breast cancer and other types. This TDP is sensitive to cisplatin chemotherapy and can be scored using a genome-based formula.
A study presented at the 2016 USCAP Conference found that HER4 expression is associated with chemotherapy resistance and a lower survival rate in ovarian serous cancer patients. The research, led by Moffitt Cancer Center pathologists, suggests that HER4 may be a prognostic and potentially predictive marker for this type of cancer.
Researchers discover small peptides psaptides that can force tumors to regress by stimulating an anti-angiogenic response in healthy tissues. Psaptides mimic the naturally occurring human protein prosaposin, which stimulates immune cells to produce a potent anti-inflammatory protein called thrombospondin-1.
A multicentre study found type 1 diabetes associated with higher cancer incidence, especially for cancers of the stomach, liver, pancreas, endometrium, ovary, and kidney. Women with type 1 diabetes had a smaller but still significant increased risk compared to men.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
A study at The Wistar Institute revealed that Satb1 expression is required for proper immune response, but its prolonged presence drives immunosuppressive behavior. Silencing Satb1 in tumor-associated dendritic cells boosted T-cell activation and reduced inflammation.
The Independent Data Monitoring Committee has recommended continuing the Phase III trial with PM1183 due to positive safety data from the first 80 patients. The trial assesses PM1183's efficacy compared to standard treatments for platinum-resistant ovarian cancer.
Researchers argue for greater support and research to help women make informed decisions about preventive mastectomies and ovary removal. The procedures can significantly reduce cancer risk but also carry risks and emotional challenges.
A study by Yale University researchers found that very few women undergo bilateral salpingectomy with ovarian conservation during hysterectomies for non-cancerous conditions. The procedure may help protect against ovarian cancer and preserve hormonal levels, but its use varies widely among hospitals across the US.
A new treatment model recommends aggressive surgery followed by targeted chemotherapy to achieve a 50% cure rate for women with advanced-stage ovarian cancer. This approach differs from current conventional treatments, which often result in a 20% survival rate.
A new algorithm assesses adnexal masses with ultrasound, identifying 89-99% of patients with ovarian cancer. The approach allows for individualized patient management and potentially levels the playing field in expert interpretation.
A study published in the Journal of the National Cancer Institute found that women carrying an inherited BRIP1 gene fault are over three times more likely to develop ovarian cancer. The research also showed that these women tend to be diagnosed with aggressive cancers at a later age and have a higher risk of dying from the disease.
Researchers found that auranofin reduces the survival rates of ovarian cancer cells with depleted BRCA1 levels, increasing their sensitivity to the drug. This suggests auranofin's potential as a clinical treatment for ovarian cancers with BRCA1 deficiency.
A study of 200,000 twin individuals found an increased cancer risk among those whose co-twin was diagnosed with cancer. The risks varied by type and were higher for monozygotic twins.
A new study published in The Lancet found that annual blood tests for ovarian cancer screening may reduce mortality rates by up to 20%. The UK Collaborative Trial of Ovarian Cancer Screening showed a delayed effect on mortality between the screening and control arms, becoming significant after seven years.
A 14-year study found that annual screening with a blood test utilizing the Risk of Ovarian Cancer Algorithm (ROCA) significantly reduced mortality from ovarian cancer, particularly in women without evidence of cancer at study entry. The results showed a 20% reduction in risk of dying from ovarian cancer.
The UKCTOCS trial found that ovarian cancer screening reduced mortality by an estimated 15-28% in the MMS group compared to no screening. Longer follow-up is needed to confirm these results and determine their cost-effectiveness.